BioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in Immuno-oncology and Neuroscience May 10, 2017
BioXcel Presents Promising Data Demonstrating BXCL701 / Anti-PD1 Combination Increases Anti-Tumor Cytokines and Tumor Growth Inhibition at 2017 AACR Annual Meeting Apr 3, 2017
BioXcel and Centrexion Therapeutics Further Advance Big Data Innovation Lab Collaboration in Chronic Pain Oct 19, 2016
BioXcel’s BXCL101, Receives Orphan Drug Designation from the U.S. FDA for the Treatment of Patients with Neurofibromatosis Type 2 (NF2) Sep 13, 2016
BioXcel Begins Strategic Collaboration with Alnylam to Discover Novel RNAi Therapeutic Products May 24, 2016
BioXcel to Present at the 3rd International Conference on the Progress of Regenerative Medicine and its Cultural Impact at the Vatican Apr 27, 2016
